论文部分内容阅读
目的探讨还原型谷胱甘肽(GSH)联合血脂康治疗高脂血症性脂肪肝的疗效。方法将120例高脂血症性脂肪肝患者随机分为治疗组(GSH+血脂康)和对照组(复方丹参注射液+护肝片),观察两组治疗前后症状、血脂、肝功能及肝脏B超影像学改变。结果经治疗后治疗组总有效率优于对照组(P<0.05);患者丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)和谷氨酰转肽酶(GGT)均明显降低,优于对照组(P<0.05或0.01);总胆固醇(TC)、甘油三酯(TG)较治疗前明显降低(P<0.01),与对照组比较差异有统计学意义(P<0.01);同时肝B超影像学总有效率也优于对照组(P<0.05)。结论 GSH联合血脂康治疗高脂血症性脂肪肝效果良好,未发现副作用。
Objective To investigate the efficacy of reduced glutathione (GSH) and Xuezhikang in the treatment of hyperlipidemic fatty liver. Methods 120 patients with hyperlipidemic fatty liver were randomly divided into treatment group (GSH + Xuezhikang) and control group (compound Danshen injection + Hugan tablet). The symptoms, blood lipids, liver function and liver function of the two groups were observed before and after treatment Hyper-imaging changes. Results After treatment, the total effective rate of the treatment group was better than that of the control group (P <0.05). The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and glutamyl transpeptidase (GGT) (P <0.05 or 0.01). The total cholesterol (TC) and triglyceride (TG) were significantly lower than those before treatment (P <0.01), and the difference was statistically significant (P <0.01). At the same time, the total effective rate of liver B ultrasound imaging was also better than that of the control group (P <0.05). Conclusion GSH combined Xuezhikang treatment of hyperlipidemic fatty liver good results, no side effects were found.